News Sentiment

AUTL sentiment intelligence

Autolus Therapeutics Ltd news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 60 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.61 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

78/100 classification confidence.

Company focus 52

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

+1.9% over one week, +3.2% over four weeks, trend active, and below fair value.

Latest direct headline Positive

Autolus Therapeutics (AUTL) Grants Inducement Awards to New Employees

Market Reaction

Balanced read

62/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 78/100 classification
One-week reaction 1.9% Price digesting
Trend fit Trend active 3.2% over four weeks
Fair value -44.6% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 15
Neutral 40
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 52
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 17
Stock Titan 16
TradingView 9
simplywall.st 5
TradingKey 3
Moomoo 2
Intellectia AI 1
www.marketscreener.com 1

Event Lens

What the news is about

Classified themes
Market update 30
Earnings 22
Analyst action 5
Regulatory and legal 1
Capital return 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 60
Market source Direct company coverage

Autolus Therapeutics (AUTL) Grants Inducement Awards to New Employees

Autolus Therapeutics (NASDAQ:AUTL) has granted stock option awards and restricted stock units to 13 new employees under its 2025 Inducement Plan. These awards, totaling 25,420 American Depositary Shares and 87,530 RSUs, were issued in accordance with Nasdaq Listing Rule 5635(c)(4

Tone
Positive 71/100
Event
Market update
Published
14 Jul 2026 10:41
Source
Market source
Intellectia AI Direct company coverage

AUTL PE Ratio & Valuation, Is AUTL Overvalued

Autolus Therapeutics PLC (AUTL) is currently considered undervalued, with its forward PS ratio of 2.20 being lower than its five-year average. The fair price for AUTL is estimated to be between $2.77 and $4.57, significantly higher than its current price of $1.58. Despite a high

Tone
Positive 66/100
Event
Market update
Published
05 Jul 2026 01:39
Source
Intellectia AI
Stock Titan Direct company coverage

Autolus awards stock grants to 13 new employees

Autolus Therapeutics (Nasdaq: AUTL) has granted equity awards to 13 new employees under its 2025 Inducement Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). These awards include options for 25,420 ADSs at an exercise price of $1.66 and 87,530 RSUs, both vesting over four

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 01:45
Source
Stock Titan
Stock Titan Direct company coverage

Autolus (NASDAQ: AUTL) director awarded 47,500 options and 31,667 RSUs

Autolus Therapeutics plc director, Cynthia M. Butitta, was granted significant equity awards, including options to purchase 47,500 American Depositary Shares (ADSs) and 31,667 restricted share units (RSUs). These awards are compensation-related, not open-market transactions, with

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 23:39
Source
Stock Titan
www.marketscreener.com Direct company coverage

Autolus Therapeutics plc Announces Termination of John Berriman as Director, Effective June 29, 2026

Autolus Therapeutics Plc announced the termination of John Berriman as Director, effective June 29, 2026. The company is an early commercial-stage biopharmaceutical company focused on developing programmed T cell therapies for cancer and autoimmune diseases, with an approved comm

Tone
Negative 39/100
Event
Market update
Published
01 Jul 2026 22:10
Source
www.marketscreener.com
Caledonian Record Direct company coverage

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Autolus Therapeutics plc announced inducement grants to 13 new employees as per Nasdaq Listing Rule 5635(c)(4). These grants include stock option awards for 25,420 American Depositary Shares and 87,530 restricted stock units, with a grant date of June 24, 2026. The awards are str

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 21:41
Source
Caledonian Record
Stock Titan Direct company coverage

Autolus Therapeutics (AUTL) director granted options and 31,667 RSUs

Autolus Therapeutics director William D. Young was granted equity-based compensation awards, including options to purchase 47,500 American Depositary Shares at an exercise price of $1.61 per share, vesting monthly over twelve installments starting July 29, 2026. He also received

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 20:22
Source
Stock Titan
Stock Titan Direct company coverage

Director at Autolus (AUTL) granted stock options and RSUs as compensation

Autolus Therapeutics plc director Rao Madduri Ravin received new equity awards, including 47,500 share options with a $1.61 exercise price and 31,667 restricted share units (RSUs). These awards are compensation-related, with options vesting monthly starting July 29, 2026, and RSU

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 20:20
Source
Stock Titan
Stock Titan Direct company coverage

Autolus Therapeutics (AUTL) director receives new option and RSU equity awards

Autolus Therapeutics director Robert Iannone was granted new equity awards, including options for 47,500 American Depositary Shares (ADSs) with an exercise price of $1.6100 per share, vesting monthly from July 29, 2026, and expiring on June 29, 2036. He also received 31,667 restr

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 20:13
Source
Stock Titan
Stock Titan Direct company coverage

Autolus Therapeutics (AUTL) director awarded new options and RSUs

Autolus Therapeutics plc director Ryan Richardson received new equity awards comprising 47,500 stock options with a $1.61 exercise price and 31,667 restricted share units (RSUs). These grants are considered standard equity compensation, not open-market transactions, and are inten

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 20:10
Source
Stock Titan
Stock Titan Direct company coverage

Autolus Therapeutics (AUTL) director gains new option and RSU awards

Autolus Therapeutics director Michael W. Bonney was granted new equity compensation, including options to purchase 47,500 American Depositary Shares at $1.61 per share and 31,667 restricted share units (RSUs). These awards are subject to time-based vesting, with options vesting m

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 20:09
Source
Stock Titan
TradingView Direct company coverage

AUTL: Expanding CAR T-cell therapy demonstrates robust efficacy, safety, and broadening market reach

Autolus Therapeutics (AUTL) is highlighted for its differentiated CAR T-cell therapy, which shows strong safety and efficacy in various settings, leading to increased adoption and revenue growth. The company is pursuing further studies for broader oncology and autoimmune applicat

Tone
Positive 74/100
Event
Earnings
Published
30 Jun 2026 21:09
Source
TradingView
Finviz Direct company coverage

AUTL - Autolus Therapeutics plc ADR Options

This article provides a detailed financial overview of Autolus Therapeutics plc (AUTL), an ADR listed healthcare biotechnology company. It includes key financial metrics such as market cap, sales, income, EPS, and various ratios, alongside performance indicators like insider and

Tone
Neutral 50/100
Event
Earnings
Published
30 Jun 2026 09:10
Source
Finviz
Stock Titan Direct company coverage

Autolus Therapeutics (NASDAQ: AUTL) passes all resolutions at 2026 AGM

Autolus Therapeutics plc (NASDAQ: AUTL) announced that all six ordinary resolutions presented at its 2026 Annual General Meeting (AGM) were approved by shareholders. These resolutions included the adoption of the 2025 Annual Report and Accounts, approval of the directors' remuner

Tone
Neutral 50/100
Event
Regulatory and legal
Published
29 Jun 2026 20:11
Source
Stock Titan
Moomoo Direct company coverage

Autolus Therapeutics to Participate in Upcoming Investor Conference

Autolus Therapeutics announced its participation in an upcoming investor conference. The company will be sharing updates and engaging with the investment community at the event. Further details about the specific conference and presentation times are anticipated to be provided.

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 00:40
Source
Moomoo
TradingView Direct company coverage

Price to book forward of Autolus Therapeutics plc – NASDAQ:AUTL

This article provides the "Price to book forward" for Autolus Therapeutics plc (NASDAQ: AUTL). It presents a financial metric within the context of the company's profile on TradingView, serving as a data point for investors researching the pharmaceutical company. The page indicat

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 13:39
Source
TradingView
TradingView Direct company coverage

Autolus Therapeutics Plc Sponsored ADR Actuals & Estimates (NASDAQ:AUTL)

This page provides financial actuals and estimates for Autolus Therapeutics Plc Sponsored ADR (NASDAQ:AUTL), allowing users to explore reported financial data and analyst estimates. It highlights key financial statements, including income, balance sheet, and cash flow, for both a

Tone
Neutral 50/100
Event
Analyst action
Published
26 Jun 2026 06:39
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Autolus Therapeutics plc – NASDAQ:AUTL

This article provides financial data on Autolus Therapeutics plc (NASDAQ: AUTL), specifically focusing on its enterprise value to EBIT forward. It indicates various financial metrics and stock market information available on the TradingView platform for the company.

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 20:12
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Autolus Therapeutics Plc Sponsored ADR – TRADEGATE:6A3A

This article provides a financial data point for Autolus Therapeutics Plc Sponsored ADR (TRADEGATE:6A3A), specifically its enterprise value to revenue forward. It appears to be a stub or a data-focused page from TradingView, displaying a key financial metric but without further d

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 14:10
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Autolus Therapeutics plc – NASDAQ:AUTL

This article provides financial information for Autolus Therapeutics plc (NASDAQ:AUTL), specifically focusing on its forward price-to-sales ratio. It lists the company's market and financial data sources, but does not present specific values for the ratio or its change over time.

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 01:09
Source
TradingView
TradingView Direct company coverage

Price to book forward of Autolus Therapeutics Plc Sponsored ADR – TRADEGATE:6A3A

This article provides financial data for Autolus Therapeutics Plc Sponsored ADR (6A3A) on the Tradegate Exchange, specifically focusing on its forward price-to-book ratio. The content is primarily a data page from TradingView, indicating the market status, and offers a glimpse in

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 00:09
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Autolus Therapeutics plc – NASDAQ:AUTL

This article displays the "Price to earnings forward" for Autolus Therapeutics plc (NASDAQ: AUTL). It presents a financial metric within a data table format, indicating that the value and change data for this specific period are made by humans. The article is primarily a display

Tone
Neutral 50/100
Event
Earnings
Published
24 Jun 2026 18:39
Source
TradingView
Market source Direct company coverage

Autolus Therapeutics (AUTL) Stock Sees Split Analyst Revisions After Early Aucatyzl Launch Signals

Analysts have provided split revisions for Autolus Therapeutics (AUTL) stock following the early commercial launch of its product, Aucatyzl. Some analysts, like H.C. Wainwright, have raised price targets to US$10 based on strong early demand signals in the U.S. and UK. Others, su

Tone
Neutral 50/100
Event
Analyst action
Published
24 Jun 2026 18:11
Source
Market source
TradingKey Direct company coverage

Autolus Therapeutics PLC (AUTL) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Autolus Therapeutics PLC's (AUTL) dividend and stock split history, noting that no dividends have been distributed in the past 5 years and there is no data on stock splits. It also includes current market data for AUTL, showing its stock price

Tone
Neutral 50/100
Event
Capital return
Published
18 Jun 2026 11:09
Source
TradingKey
TradingKey Direct company coverage

Autolus Therapeutics PLC (AUTL) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the major shareholders and institutional holdings of Autolus Therapeutics PLC (AUTL), providing a breakdown of shareholder types and their proportional ownership. Key investors include BioNTech SE, Syncona Investment Management Limited, and MAK Capital One, L

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 10:09
Source
TradingKey